Avatar photo

Dr. D. Beard

DR. D. BEARD is specialist of Nash Pathology
  • Articles: 191
Videos & Slides: 0

Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.

Nowadays, dramatic changes in the lifestyle and diet of the global population are causing the prevalence of NAFLD increasing rapidly, in parallel with that of obesity and diabetes. Previous studies found an inverse relationship between physical activity and the risk of NAFLD. However, clinical trials...
Read MorePhysical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.

Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.

In this study, J. Boeckmans et al. (Faculty of Medicine and Pharmacy, Vrije Universiteit, Brussels, Belgium) reproduced key NASH characteristics in vitro by exposing primary human hepatocytes, human skin stem cell-derived hepatic cells, HepaRG and HepG2 cell lines, as well as LX-2 hepatic stellate cells to multiple factors that play a role in the onset of NASH...

Read MoreHuman hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.

Awareness of Non-alcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort.

Low awareness can delay healthcare screening and prevention of NAFLD and its related complications. Therefore, low awareness of NAFLD among the general population is a matter of great concern. This is also important for resource allocation, and the creation and implementation of awareness programs....
Read MoreAwareness of Non-alcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort.

Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.

Some studies showed that the effect of SGLT2 inhibitors on weight loss was useful for the alleviation of NAFLD and SGLT2 inhibitors can significantly reduce bodyweight in NAFLD patients. In addition, a recent cohort study suggested that the administration of SGLT2 inhibitors to patients with type 2 diabetes mellitus could...
Read MoreEffects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.

The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease.

NAFLD is closely related to features of the metabolic syndrome including type 2 diabetes. P. Nasr et al. (Linköping University, Sweden) investigated the importance of the amount of liver fat on mortality and the risk of developing type 2 diabetes. In 129 patients with biopsy proven NAFLD prospectively...
Read MoreThe amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease.

Correlation between serum 25-OH vitamin D expression and non-alcoholic fatty liver disease.

J. Cai et al. (Department of Geriatric Medicine, Zhongshan Hospital, Xiamen, P.R. China) investigated changes in the level of serum 25-OH vitamin D [25-hydroxyvitamin D, 25(OH)D] in patients with NAFLD and the correlation between the severity of NAFLD and 25(OH)D. Their retrospective analysis was performed on 385 NAFLD patients and 347 healthy people...
Read MoreCorrelation between serum 25-OH vitamin D expression and non-alcoholic fatty liver disease.

Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial.

Cilofexor is a small molecule nonsteroidal agonist of farnesoid X receptor (FXR). K. Patel et al. (University of Toronto, Canada) evaluated the safety and efficacy of cilofexor in patients with NASH in a double-blind, placebo-controlled, phase 2 trial. 140 non-cirrhotic patients with NASH were randomized to receive cilofexor...
Read MoreCilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial.

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Apoptosis signal-regulating kinase 1 (ASK1) plays a key role in hepatocyte injury, inflammation, and fibrosis in nonalcoholic steatohepatitis (NASH). Selonsertib is an investigational selective inhibitor of ASK1. In order to evaluate the safety and anti-fibrotic effect of selonsertib, Stephen A. Harrison et al...
Read MoreSelonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Non-Alcoholic Fatty Liver Disease and Vascular Disease.

Non-Alcoholic Fatty Liver Disease (NAFLD) represents an increasing cause of liver disease worldwide. However, notably, the primary cause of morbidity and mortality in patients with NAFLD is cardiovascular disease (CVD), with fibrosis stage being the strongest disease-specific predictor. Within the next few years, NAFLD will contribute considerably to the overall...
Read MoreNon-Alcoholic Fatty Liver Disease and Vascular Disease.

The risk of atrial fibrillation in patients with non-alcoholic fatty liver disease and a high hepatic fibrosis index.

Epidemiological studies focusing on the association between liver disease and atrial fibrillation show inconsistent findings. Patients with liver disease have a higher atrial fibrillation risk. A recent meta-analysis by Karn Wijarnpreecha et al. (Department of Internal Medicine, Bassett Medical Centre, Cooperstown, NY, USA), published...
Read MoreThe risk of atrial fibrillation in patients with non-alcoholic fatty liver disease and a high hepatic fibrosis index.

Association of serum vitamin D level and nonalcoholic fatty liver disease: a meta-analysis.

T. Liu et al. aimed to explore the potential link of serum vitamin D level with NAFLD. Of the 309 initially retrieved studies, 15 studies of high quality involving a total of 20 096 participants (including 7803 NAFLD patients) were included in this meta-analysis. Meta-analysis of continuous data indicated that NAFLD patients...
Read MoreAssociation of serum vitamin D level and nonalcoholic fatty liver disease: a meta-analysis.

Vitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients.

Liver disease is common among patients infected with HIV. The proportion of deaths caused by liver-related aetiologies has increased between 8 to 10-fold in the post-antiretroviral therapy (ART) era while AIDS-related mortality has fallen more than 90-fold. NAFLD is an important contributor to this trend. Higher rates of the...
Read MoreVitamin E is an effective treatment for nonalcoholic steatohepatitis in HIV mono-infected patients.